24/7 Patient Assistance: 760-405-8205
24/7 Patient Assistance: 760-405-8205
Hospitals & Clinics
specialties & services
Drexel University College of Medicine
Medical School
Shands Jacksonville Medical Center
Internship
Edward W Sparrow Hospital
Residency
Shands Jacksonville Medical Center
Residency
UCSF
Fellowship
American Board of Internal Medicine - Oncology
Marin General Hospital
Languages: English/Spanish
(415) 925-7000
250 Bon Air Rd
Greenbrae, California 94904 
A Phase I Dose Escalation and Expansion Study of the Anticancer Stem Cell Agent Demcizumab (Anti-DLL4) in Patients with Previously Treated Solid Tumors.
Smith, D. C.,Eisenberg, P. D.,Manikhas, G.,Chugh, R.,Gubens, M. A.,Stagg, R. J.,Kapoun, A. M.,Xu, L.,Dupont, J.,Sikic, B.; Clin. Cancer Res.. 2014 Oct 18.
See more >>
Sorafenib or Placebo with Either Gemcitabine or Capecitabine in Patients with HER-2-Negative Advanced Breast Cancer That Progressed during or after Bevacizumab.
Schwartzberg, L. S.,Tauer, K. W.,Hermann, R. C.,Makari-Judson, G.,Isaacs, C.,Beck, J. T.,Kaklamani, V.,Stepanski, E. J.,Rugo, H. S.,Wang, W.,Bell-McGuinn, K.,Kirshner,...; Clin. Cancer Res.. 2013 May 15.
See more >>
Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma.
Choueiri, T. K., Vaishampayan, U., Rosenberg, J. E., Logan, T. F., Harzstark, A. L., Bukowski, R. M., Rini, B. I., Srinivas, S., Stein, M. N., Adams, L. M., Ottesen, L...; J Clin Oncol. 2013 Jan 10.
See more >>